You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Relapsed/Refractory Mantle Cell Lymphoma: How Would You Care for These Virtual Patients?

  1. A 78-year-old man with a history of MCL presents with increasing fatigue and worsening lymphadenopathy while on second-line targeted therapy. Which of the following tests must be performed to appropriately evaluate this patient?
    Biomarker testing for Ki-67 level and TP53 mutations
    Histologic evaluation of a lymph node biopsy
    Positron emission tomography/computed tomography (PET/CT)
    Pulmonary function testing
  2. A 67-year-old woman with MCL was treated with second-line acalabrutinib for 2 years. She developed increasing fatigue and worsening lymphadenopathy and was found to have progressive disease. Based on current guidelines and clinical data, which third-line therapy is most appropriate?
    Axicabtagene ciloleucel or brexucabtagene autoleucel
    Pirtobrutinib or brexucabtagene autoleucel
    Pirtobrutinib or zanubrutinib
    Zanubrutinib or axicabtagene ciloleucel
  3. A 70-year-old man is diagnosed with R/R MCL approximately 5 years after first-line bendamustine/rituximab. He is getting ready to begin a BTK inhibitor as second-line therapy. As you discuss potential adverse events and strategies to prevent these events, which of the following is most commonly associated with BTK inhibitor therapies and should be included in the discussion?
    Cytokine release syndrome
    Infection risk
    Ocular toxicity